Author/Editor		Ahčan, Jerneja; Čižman, Milan; Pleterski-Rigler, Dušica; Rakar, Rasta
Title		Ocena upravičenosti splošnega cepljenja otrok proti noricam v Sloveniji
Translated title		Value of universal childhood varicella vaccination in Slovenia
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 71, št. 11
Publication year		2002
Volume		str. 667-72
Language		slo
Abstract		Background. In 1974 effective and safe vaccine against varicella was developed. Vaccination is recomended for universal childhood immunisation in some of west European countries and in the United States. The aim of the study was to perform economicanalysis of universal childhood vaccination against varicella in Slovenia. Methods. We examined hypothetical birth cohort of 5800 persons followed from birth to their 30th birthday and calculated the cost-benefit ratio for varicella vaccination program. We assumed that one dose of vaccine would begiven to 15-monthold children along with measles, mumps and rubella vaccination. It was also assumed that 95% of children would be vaccinated, that vaccine efficacy would be 90% that vaccine induced immunity would be lifelong and that the program would have no effect on either the incidence rate or severity of herpes zoster. For both disease and vaccine we measured the direct medical cost and indirect cost. Results. Indirect cost represented major part compared to medical cost. The benefit to cost ratio was 0.89. Conclusions. Considering major assumptions in this analysis, there is no financial benefits from vaccinating all children against varicella tn our country.
Summary		Izhodišča. Leta 1974 so razvili varno in učinkovito cepivo proti noricam. Cepljenje priporočajo za splošno cepljenje otrok v nekaterih zahodnoevropskih državah in v ZDA. V raziskavi smo analizirah ekonomsko upravičenost uvedbe splošnega cepljenja otrok proti noricam v Sloveniji. Metode. Za hipotetično kohorto 5800 letno rojenih otrok, ki smo jo spremljali od rojstva do 30. leta, smo izračunali količnik koristi in stroškov splošnega cepljenja otrok proti noricam. Pri izračunu smo predpostavili, da bodo otroci cepljeni z enim odmerkom cepiva proti noricam pri 15. mesecih, sočasno s cepljenjem proti mumpsu, ošpicam in rdečkam. Predpostavili smo, da bo precepljenost 95% in učinkovitost cepiva 90%, imunost po cepljenju doživljenjska in da cepljenje ne bo imelo vpliva na večje pojavljanje ali težji potek herpes zostra. Izmerili smo medicinske in nemedicinske stroške za programa cepljenih in necepljenih otrok in ju primerjali. Rezultati. Nemedicinski stroški so v primerjavi z medicinskimi predstavljali večji delež. Izračunali smo, da je količnik koristi in stroškov 0,89. Zaključki. Ob upoštevanju glavnih predpostavk v naši analizi splošno cepljenje otrok proti noricam z ekonomskega vidika pri nas ni upravičeno.
Descriptors		CHICKENPOX CHICKENPOX VACCINE COST-BENEFIT ANALYSIS CHILD DRUG COSTS